EN DE
Watch Venus Medtech Hangzhou Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Venus Medtech Hangzhou Inc (2500) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Venus Medtech Hangzhou Inc stock HK$1.14, price HK$0.99, upside +15.2%, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100003PJ8

VM Venus Medtech Hangzhou Inc logo Thin data Nov 10, 2026

Venus Medtech Hangzhou Inc

2500 · HK

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value HK$1.14 · Fairly valued 
Quality 42/100 
Mixed vs. peers (4/10) 
Revenue last quarter 28% below a year ago. 
Falling price (downtrend) 
Weak Growth (revenue 3y −9.0 %/yr in CNY) 
Loss-making · -182.0% net margin (TTM) 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Venus Medtech Hangzhou Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$63.95 HK$0.9650 Fair Value HK$1.14 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.9650 – HK$63.95 · fair‑value band HK$0.8500 – HK$1.42 · the HK$0.9900 price screens below the HK$1.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Venus Medtech Hangzhou in your weekly email

Every Wednesday you see whether Venus Medtech Hangzhou is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.

Show moreShow less

The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis.

It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; and renal artery denervation ablation system for the treatment of hypertension.

In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Stock analysis

Venus Medtech Hangzhou Inc (2500) currently trades at HK$0.9900, while our estimate is HK$1.14, so the stock looks roughly fairly valued today (gap 13.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.8500 (bear) to HK$1.42 (bull), the price of HK$0.9900 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Venus Medtech Hangzhou Inc reported revenue of 307M CNY in FY2025 versus 416M CNY in FY2021, a compound −7.3%/yr. Reported net income was −408M CNY in FY2025.

Key figures

Market cap HK$434M (≈ $55.3M) Micro · P/S ratio 1.72 · Net margin −133% · Return on equity −25.9% · Return on assets (EBIT) −11.1% (5-year average) · Operating margin −126% · Revenue (TTM) 255M CNY · Revenue growth (YoY) −27.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 15%, 2500 screens cheaper than that median.

Fair Value

Bear HK$0.8500 Fair Value HK$1.14 Bull HK$1.42
Price HK$0.9900 · Upside +15.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−34.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.7% (2020) → −112.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2500, get fair value alerts →

Compare Venus Medtech Hangzhou Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside +15.2% · Top 25%
Profitability
Return on assets −16.2% · Below median
Net margin (12 months) −182.0% · Bottom 25%
Operating margin (12 months) −125.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −27.6% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.21× · Cheapest 25%
P/S (12 months) 1.45× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)54 · sector 17
FUTURE (revenue growth)0 · sector 41
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $343.63 +11% vs 2500
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs 2500
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 2500
DexCom, Inc DXCM $83.33 $91.66 +10% vs 2500
STERIS plc STE $264.32 $281.90 +7% vs 2500
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 2500
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 2500
Medtronic plc MDT $102.86 $74.90 −27% vs 2500
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 2500
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 2500

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Venus Medtech Hangzhou Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Venus Medtech Hangzhou Inc Fair Value". https://www.fairvalue-calculator.com/stock/2500

Frequently asked questions

Is Venus Medtech Hangzhou Inc (2500) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$1.14 versus a price of HK$0.9900, about +15% upside (fairly valued).
What is the fair value of 2500?
Our estimate for Venus Medtech Hangzhou Inc is HK$1.14 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.9900.
What is the quality score of 2500?
Venus Medtech Hangzhou Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Venus Medtech Hangzhou Inc (2500)?
Our calculated price target is the estimate of HK$1.14 (as of Nov 10, 2026). Cautious scenario HK$0.8500, optimistic scenario HK$1.42. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Venus Medtech Hangzhou Inc stock forecast for 2026?
Our estimate puts fair value at HK$1.14, about +15% upside versus a price of HK$0.9900 (fairly valued). Cautious scenario HK$0.8500, optimistic scenario HK$1.42. The calculation is refreshed regularly with new filings.
What is the revenue of Venus Medtech Hangzhou Inc (2500)?
Venus Medtech Hangzhou Inc reported trailing-twelve-month revenue of about 255M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Venus Medtech Hangzhou Inc (2500)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Venus Medtech Hangzhou Inc it is HK$1.14 per share (as of Nov 10, 2026), against a price of HK$0.9900.
Is Venus Medtech Hangzhou Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2500 trades below its calculated fair value: price HK$0.9900, fair value HK$1.14, a gap of about +15% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2500?
No. The price is what the market pays today (HK$0.9900); the fair value is what the company's own numbers justify (HK$1.14). For Venus Medtech Hangzhou Inc the two are HK$0.1500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Venus Medtech Hangzhou Inc worth?
The market values Venus Medtech Hangzhou Inc at about HK$434M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.9900; our models calculate a fair value of HK$1.14 per share.
What do the bullish and bearish scenarios say about 2500?
Our models span a range for Venus Medtech Hangzhou Inc: cautious scenario HK$0.8500, base HK$1.14, optimistic HK$1.42 per share (as of Nov 10, 2026, price HK$0.9900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Venus Medtech Hangzhou Inc (2500)?
Balance-sheet figures for Venus Medtech Hangzhou Inc (as of Nov 10, 2026): return on equity −25.9%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 2500 from its 52-week high?
Venus Medtech Hangzhou Inc trades at HK$0.9900, about 72% below its 52-week high of HK$3.57 and 3% above the low of HK$0.9650 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.14 is for.
Which stocks are comparable to Venus Medtech Hangzhou Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Venus Medtech Hangzhou Inc stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.9900, calculated fair value HK$1.14 (+15%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Venus Medtech Hangzhou Inc currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Venus Medtech Hangzhou Inc (2500)?
The closing price on Nov 13, 2026 was HK$0.9900. Our estimate is HK$1.14, about +15% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Venus Medtech Hangzhou Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Venus Medtech Hangzhou Inc

How large is the market capitalisation of Venus Medtech Hangzhou Inc (2500)?
The market capitalisation of Venus Medtech Hangzhou Inc is HK$434M (≈ $55.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Venus Medtech Hangzhou Inc (2500)?
The price-to-sales ratio of Venus Medtech Hangzhou Inc is 1.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Venus Medtech Hangzhou Inc (2500)?
The net margin of Venus Medtech Hangzhou Inc is −133% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Venus Medtech Hangzhou Inc (2500)?
The return on equity (ROE) of Venus Medtech Hangzhou Inc is −25.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Venus Medtech Hangzhou Inc (2500)?
On an EBIT basis the return on assets of Venus Medtech Hangzhou Inc is −11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Venus Medtech Hangzhou Inc (2500)?
The operating margin of Venus Medtech Hangzhou Inc is −126% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Venus Medtech Hangzhou Inc (2500)?
Revenue at Venus Medtech Hangzhou Inc is down 27.6% versus a year earlier (3y avg −9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Venus Medtech Hangzhou Inc (2500) generate?
The free cash flow of Venus Medtech Hangzhou Inc is −332M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Venus Medtech Hangzhou Inc (2500) carry?
The net debt of Venus Medtech Hangzhou Inc is 41.4M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Venus Medtech Hangzhou Inc in the live analysis

One click puts Venus Medtech Hangzhou Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.